Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

This study is comparing radiation therapy plus nimotuzumab (a targeted antibody drug) against radiation therapy alone for patients with locally advanced head and neck cancer who cannot receive standard platinum-based chemotherapy (usually cisplatin) due to their health. **You may be eligible if...** - You are 18 or older with confirmed stage III–IVB head and neck squamous cell cancer (mouth, throat, voice box, or lower throat) - Surgery is not an option for you - You are not able to tolerate cisplatin chemotherapy (e.g., due to age 65+, kidney problems, hearing loss, nerve damage, or poor performance status) - You are suitable for definitive (curative-intent) radiation therapy **You may NOT be eligible if...** - You are able to receive standard cisplatin chemotherapy - Your cancer has spread to distant organs (stage IVC, if not eligible for the study criteria) - You have had prior radiation, chemotherapy, or other cancer treatment for this tumor - You have significant heart, kidney, or liver problems Talk to your doctor to see if this trial is right for you.